PARIS, France, September 6 /PRNewswire/ -- Aureus Pharma a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announced today the appointment of Jason Theodosiou as Chief Operating Officer and also as member of the Aureus Board of Directors. In this new position, Dr. Theodosiou will be responsible for directing the company’s worldwide operations including commercial efforts.
Dr. Theodosiou brings extensive experience in the Life Science Informatics industry where he has held various senior management positions. Most recently he was Vice President for Global Business at Elsevier MDL and at Lion Biosciences. He also has held positions of General Manager for European Operations at EMAX/SciQUEST He holds a BSc/MSc and Ph.D. in Organic Chemistry from the University of Aix-Marseilles as well as an Executive MBA from the ESCP Business School of Paris.
“We are very excited to welcome Jason Theodosiou to Aureus Pharma,” said Dr. Andre Michel, Aureus’ CEO. “His leadership and business experience will be important assets to both Aureus Pharma and our customers. We are looking forward to his contributions to the strategic directions and executive management of our company.”
“Aureus Pharma is a dynamic and innovative company with a high quality knowledge database product portfolio and a recognized expertise in the market,” said Theosodiou whose expertise is delivering highly customer focused solutions to the drug discovery industry.” I am pleased to join the company and I look forward to further growing the company’s global operations and customer base.”
About Aureus Pharma
Aureus Pharma headquartered in Paris, France is a privately held knowledge management based solutions provider for the life sciences industry. Aureus Pharma accelerates new drug discovery by providing knowledge databases which contain high quality quantitative information for both chemistry and biology. Researchers gain rapid access to knowledge for important drug target classes including GPCR, Ion Channel, Kinase as well as other critical pharmaceutical topics including ADME/Drug-Drug Interactions and the hERG Channel. The information contained in the Aureus Pharma system is of primary importance to aid in lead discovery and optimization as well as to build predictive models. For further information on how Aureus Pharma helps researchers turn data into discovery visit www.aureus-pharma.com
Media Contact:
For Aureus Pharma: Mary E. Donlan, Ph.D Director of Marketing & Sales +33-1-40-18-57-59/+33-6-76-19-51-77 mary.donlan@aureus-pharma.com
Source: Aureus Pharma
